-
Mashup Score: 0Stakeholder views on requiring diagnosis or clinical indication on e-prescriptions | Journal of Managed Care & Specialty Pharmacy - 5 day(s) ago
BACKGROUND: Medication safety organizations have been recommending the inclusion of diagnosis or clinical indication on prescription orders for decades. However, this information is typically not provided by prescribers and shared with pharmacists, despite the availability of data fields in the most commonly used standard for electronic prescriptions. OBJECTIVE: To elucidate the views of selected industry stakeholders relative to perceived barriers to including diagnosis or indication on all electronic prescriptions. METHODS: Semistructured concept elicitation interviews identified key issues. Survey items were refined iteratively by the research team. The final instrument consisted of 34 questions intended to elicit the importance and relative priority of perceived barriers and potential solutions. A link to the Internet survey was emailed to members of the National Council for Prescription Drug Programs in February 2023, with biweekly follow-up reminders. RESULTS: A total of 139 surv
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 0AMCP Format for Formulary Submissions 5.0 - 11 day(s) ago
VIEW ALL METRICS Select the citation format you wish to export for this article or chapter. Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled. Can’t sign in? Forgot your username? Can’t sign in? Forgot your password?
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Themed issue on drug pricing policy and the Inflation Reduction Act - 1 month(s) ago
This themed issue of the Journal of Managed Care & Specialty Pharmacy (JMCP) features articles exploring drug pricing policy, with a special focus on implementation of the Inflation Reduction Act drug pricing provisions. The Inflation Reduction Act of 2022 authorizes the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of top-selling Medicare Part B and D drugs with pharmaceutical manufacturers. How CMS implements this program has important implications for managed care pharmacy.
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 0AMCP Format for Formulary Submissions 5.0 - 1 month(s) ago
VIEW ALL METRICS Select the citation format you wish to export for this article or chapter. Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled. Can’t sign in? Forgot your username? Can’t sign in? Forgot your password?
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 4A primer on formulary structures and strategies - 1 month(s) ago
Formularies are a tool for managing costs, optimizing patient access, and improving overall health outcomes. The general goal of formularies is to provide access to appropriate therapy while promoting effective resource utilization, which allows the managed care pharmacy organization to operate sustainably. Traditional formulary strategies have included open and closed formularies as well as tiered formularies. However, other formulary structures have emerged in support of the focus on product value. The formulary development process is primarily driven by the pharmacy and therapeutics (P&T) committee and value committee within an organization. Key considerations such as member population, regional differences, regulatory/compliance implications, and benefit design strategies may influence payers to create a customized formulary to provide additional value to their members while managing costs. With the rise of high-cost and specialty products, formularies continue to serve as an impor
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 0A summit on amplifying voices of patients, caregivers, and people with disabilities in Inflation Reduction Act drug price negotiations - 2 month(s) ago
On September 18, 2023, Cancer Support Community convened patient and caregiver advocates, health care providers, policy experts, and health care innovators and thought leaders for a roundtable discussion on the need to ensure that patients, people with disabilities, and caregivers have a voice in defining “clinical benefit” for the purpose of Medicare Part D drug price negotiations and future health care policies that impact patients. The meeting featured presentations from Lara Strawbridge, Deputy Director for Policy at the Medicare Drug Rebate and Negotiations Group in the Center for Medicare, regulatory expert, Dr Monique Nolan, Counsel at Arnold and Porter, LLP, and 3 panel discussions: IRA Implementation—What Matters to Patients, a discussion of policies expected to impact patients and caregivers who are likely to rely heavily on high-cost drugs or biologics to treat cancer or other chronic illnesses, as well as the future development of novel therapies; The Science of Measuring P
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Themed issue on drug pricing policy and the Inflation Reduction Act - 2 month(s) ago
This themed issue of the Journal of Managed Care & Specialty Pharmacy (JMCP) features articles exploring drug pricing policy, with a special focus on implementation of the Inflation Reduction Act drug pricing provisions. The Inflation Reduction Act of 2022 authorizes the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of top-selling Medicare Part B and D drugs with pharmaceutical manufacturers. How CMS implements this program has important implications for managed care pharmacy.
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
Branded prescription drug reimbursement in the United States is complex and comprises multiple transactions among the parties involved in the drug supply chain, including manufacturers, wholesalers, pharmacies, health care providers, health plans or insurers, pharmacy benefit managers, and patients. This primer provides an overview of the parties involved in the reimbursement of brand-name drugs under both the pharmacy and medical benefits of an insurance policy and the flow of products and payments among them. Prescription drug spending in the United States grew from $30 billion in 1980 to $335 billion in 2018, and 80% of spending is on brand-name drugs.1,2 Pharmaceutical spending and drug prices have been the focus of intense debate in recent years, which has brought attention to the complexity of the drug supply chain. This primer provides a high-level overview of the distribution and reimbursement of brand-name drugs (italicized words are defined in the Glossary) used in the outpat
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 0Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease - 5 month(s) ago
BACKGROUND: Including pharmacists on care teams of patients with type 2 diabetes (T2D) has been shown to promote guideline-based prescribing and improve glycemic control, lowering risks of adverse cardiovascular outcomes. Evidence is lacking regarding whether including pharmacists on the care team is associated with the prescribing of GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) recommended for use in patients with T2D and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To assess the association between having a pharmacist on the primary care team of patients with T2D and ASCVD and being prescribed a guideline-recommended GLP-1 RA or SGLT-2i. METHODS: A cross-sectional analysis of patients with T2D and ASCVD seen by primary care providers at an academic medical center between June 2019 and May 2020 was completed. Patients with prescriptions for GLP-1 RA or SGLT-2i with evidence of cardiovascular benefit were identified and compared between those with ph
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet-
In the December issue of #JMCP, researchers describe the primary care pharmacist’s impact on the prescribing of GLP-1 receptor agonists and SGLT-2 inhibitors in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Learn more: https://t.co/cdZC0Tt9j7 #pharmacy https://t.co/3QGYn7RiFK
-
-
Mashup Score: 0Gene therapies for sickle cell disease: Effectiveness and value - 6 month(s) ago
Sickle cell disease (SCD) is an extremely debilitating genetic disorder affecting the shape and function of red blood cells, leading to recurrent painful vaso-occlusive crises (VOCs) and a number of serious, and potentially life-threatening, health complications, both acute and chronic. 1 Patients start experiencing symptoms in early childhood and are at risk for progressive organ damage, which translates into an estimated 20-year reduction in life expectancy compared with the general US population. 2
Source: www.jmcp.orgCategories: General Medicine News, PayerTweet
Should documenting a diagnosis code or indication on an e-prescription be required? Data from a recent survey of key industry stakeholders suggests near unanimous agreement that this could improve patient health & safety outcomes. Read more in #JMCP https://t.co/vw2Hu48BMm https://t.co/dXkhdUHTcq